


**TNP-ATP**

2',3'-O-Trinitrophenyl-adenosine-5'-triphosphate, Triethylammonium salt

Cat. No.	Amount
NU-221S	200 µl (10 mM)
NU-221L	5 x 200 µl (10 mM)

 $\lambda_{em}$  552 nm

Structural formula of TNP-ATP

**For research use only!****Shipping:** shipped on gel packs**Storage Conditions:** store at -20 °C

Short term exposure (up to 1 week cumulative) to ambient temperature possible.

**Shelf Life:** 12 months after date of delivery**Molecular Formula:** C<sub>16</sub>H<sub>17</sub>N<sub>8</sub>O<sub>19</sub>P<sub>3</sub>**Molecular Weight:** 718.27 g/mol**Exact Mass:** 717.98 g/mol**CAS#:** 120360-48-7**Purity:** ≥ 95 % (HPLC)**Form:** solution in water**Color:** orange**Concentration:** 10 mM - 11 mM**pH:** 7.5 ± 0.5**Spectroscopic Properties:**  $\lambda_{max}$  259/408/470 nm,  $\epsilon$  25.0/26.4/18.5 L mmol<sup>-1</sup> cm<sup>-1</sup> (Tris-HCl pH 7.5),  $\lambda_{exc}$  408/470 nm,

**TNP-ATP**

2',3'-O-Trinitrophenyl-adenosine-5'-triphosphate, Triethylammonium salt

**Applications:**

Agonistic ligand, mainly for nucleoside receptor A<sub>1</sub>  
Nucleoside-triphosphates can be converted by different membrane-bound phosphatases into nucleosides acting as nucleoside receptor ligands. The ester form is protected during uptake and transport and can be well-directed released through activation.

**Specific Ligands:**Ligand for purinergic receptors:P2X<sub>1</sub>, P2X<sub>2</sub><sup>[1]</sup>Antagonist for purinergic receptors:P2X<sub>1</sub><sup>[2,3]</sup>, P2X<sub>3</sub><sup>[3,6]</sup>, P2X<sub>4</sub><sup>[4]</sup>, P2X<sub>5</sub><sup>[5,7]</sup>**Selected References:**

[1] Linan-Rico *et al.* (2015) Neuropharmacology of purinergic receptors in human sub- mucous plexus: Involvement of P2X<sub>1</sub>, P2X<sub>2</sub>, P2X<sub>3</sub> channels, P2Y and A3 metabotropic receptors in neurotransmission. *Neuropharmacology* **95**:83.

[2] Kur *et al.* (2014) Purinergic control of vascular tone in retina. *J. Physiol.* **592** (3):491.

[3] Alkayed *et al.* (2012) P2Y<sub>11</sub> purinoceptor mediates the ATP-enhanced chemotactic response of neutrophils. *J. Pharmacol. Sci.* **120** (4):288.

[4] Manohar *et al.* (2012) ATP release and autocrine signaling Through P2X<sub>4</sub> receptors regulate ?? T cell activation. *J. Leukoc. Biol.* **92** (4):787.

[5] Kamai *et al.* (2006) Involvement of ionotropic purinergic receptors in the histamine-induced enhancement of the cough reflex sensitivity in guinea pigs. *Eur. J. Pharmacol.* **547** (1-3):160.

[6] Jarvis *et al.* (2001) Modulation of BzATP and formalin induced nociception: attenuation by the P2X receptor antagonist, TNP-ATP and enhancement by the P2X<sub>3</sub> allosteric modulator, cibatron blue. *Br. J. Pharmacol.* **132**:259.

[7] Ruan *et al.* (2004) Identification of P2X receptors in cultured mouse and rat parasympathetic otic ganglion neurones including P2X knockout studies. *Neuropharmacology* **46**:1039.

Seifert *et al.* (2012) Inhibitors of membranous adenylyl cyclases. *Trends Pharmacol. Sci.* **33** (2):64.

Adina-Zada *et al.* (2011) Probing the allosteric activation of pyruvate carboxylase using 2',3'-O- (2,4,6-trinitrophenyl) adenosine 5'-triphosphate as a fluorescent mimic of the allosteric activator acetyl CoA. *Arch. Biochem. Biophys.* **509** (2):117.

Volonte *et al.* (2009) Membrane components and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. *FEBS J.* **276**:318.

Yegutkin (2008) Nucleotide and nucleoside converting enzymes: Important modulators of purinergic signalling cascade. *Biochim. Biophys. Acta* **1783**:673.

Goettle *et al.* (2007) Molecular analysis of the interaction of Bordetella pertussis adenylyl cyclase with fluorescent nucleotides. *Molecular Pharmacology* **72** (3):526.

Sprang *et al.* (2006) Broad Specificity of Mammalian Adenylyl Cyclase for Interaction with 2',3'-Substituted Purine- and Pyrimidine Nucleotide Inhibitors. *Mol. Pharmacol.* **70**:878.

Berman *et al.* (2003) Interaction of an aromatic dibromoisothiuronium derivative with the Ca (2+)-ATPase of skeletal muscle sarcoplasmic reticulum. *Biochemistry* **42**:3556.

Milgrom *et al.* (1998) Bi-site activation occurs with the native and nucleotide-depleted mitochondrial F1-ATPase. *Biochem J.* **330**:1037.

Faller *et al.* (1990) Binding of the fluorescent substrate analogue 2',3'-O- (2,4,6-trinitrophenyl)cyclohexadienylidene)-adenosine 5'-triphosphate to the gastric H<sup>+</sup>,K<sup>+</sup> (+)-ATPase: evidence for cofactor-induced conformational changes in the enzyme. *Biochemistry* **29**:3179.

Hiratsuka *et al.* (1982) Biological activities and spectroscopic properties of chromophoric and fluorescent analogs of adenine nucleoside and nucleotides, 2',3'-O- (2,4,6-trinitrocyclohexadienylidene) adenosine derivatives. *Biochim Biophys Acta.* **719**:509.